2024

Abdominal Aspergillosis – an Underdiagnosed Disease? Three Cases of Abdominal Aspergillosis in Severely Immunocompromised Infants
Hauch R, Jankofsky M, Klohs S, Herden U, Blohm M, Winkler B
KLIN PADIATR. 2024;236(3):189-192.

2023

Elevated RIPK3 correlates with disease burden in myelofibrosis
Dill V, Wagner C, Keller E, Fernandez-Hernandez F, Shoumariyeh K, Odinius T, Buschhorn L, Hauch R, Suren C, Hecker J, Herhaus P, Sandherr M, Schmidt B, Slotta-Huspenina J, Bassermann F, Höckendorf U, Jilg S, Branca C, Vosberg S, Jost P
BLOOD ADV. 2023;7(7):1219-1224.

Correction: Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT
Hauch R, Hinrichs M, Ruhwald R, Schrum J, Rutkowski S, Woessmann W, Winkler B
KLIN PADIATR. 2023;235(3):e1-e2.

Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT: A Monocentric, Retrospective Study
Hauch R, Hinrichs M, Ruhwald R, Schrum J, Rutkowski S, Woessmann W, Winkler B
KLIN PADIATR. 2023;235(3):159-166.

2022

Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies
Odinius T, Buschhorn L, Wagner C, Hauch R, Dill V, Dechant M, Buck M, Shoumariyeh K, Moog P, Schwaab J, Reiter A, Brockow K, Götze K, Bassermann F, Höckendorf U, Branca C, Jost P, Jilg S
J CANCER RES CLIN. 2022;148(2):331-340.

2019

Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis
Dill V, Kauschinger J, Hauch R, Buschhorn L, Odinius T, Müller-Thomas C, Mishra R, Kyncl M, Schmidt B, Prodinger P, Hempel D, Bellos F, Höllein A, Kern W, Haferlach T, Slotta-Huspenina J, Bassermann F, Peschel C, Götze K, Waizenegger I, Höckendorf U, Jost P, Jilg S
EUR J HAEMATOL. 2019;104(2):125-137.

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
Jilg S, Hauch R, Kauschinger J, Buschhorn L, Odinius T, Dill V, Müller-Thomas C, Herold T, Prodinger P, Schmidt B, Hempel D, Bassermann F, Peschel C, Götze K, Höckendorf U, Haferlach T, Jost P
EXP HEMATOL ONCOL. 2019;8:9.

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile
Reidel V, Kauschinger J, Hauch R, Müller-Thomas C, Nadarajah N, Burgkart R, Schmidt B, Hempel D, Jacob A, Slotta-Huspenina J, Höckendorf U, Peschel C, Kern W, Haferlach T, Götze K, Jilg S, Jost P
ONCOTARGET. 2019;9(25):17270-17281.

Letzte Aktualisierung aus dem FIS: 20.12.2024 - 23:33 Uhr